share_log
Moomoo 24/7 ·  03/14 09:47

Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma 宣布,对铂耐药 ARID1A 突变卵巢癌的 NXP800 1b 期临床试验疗效进行评估的患者中,观察到的反应率为 33%,疾病控制率为 100%

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发